Table 1. Characteristics of included studies of biliary tract cancer treatment.
| Study | Country | Design | Follow-up | Treatment 1 | Treatment 2 | Outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Size | Treatment | Age (range) | Man (%) | Size | Treatment | Age (range) | Man (%) | |||||
| Chen, 2015 | China | RCT | 27 | 60 | GEM+PLA | 59(32-80) | 50 | 62 | GEM+PLA+TAR | 61(32-78) | 45 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Fiteni, 2014 | France | Retro | 24 | 44 | GEM+PLA | - | 66 | 20 | GEM+FU | - | 45 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Kang, 2012 | Korea | RCT | 36 | 49 | GEM+PLA | 59(32-77) | 63 | 47 | FU+PLA | 60(36-77) | 92 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Lee, 2015 | Korea | Retro | 24 | 49 | GEM+PLA | 65(45-81) | 63.3 | 44 | FU+PLA | 65(39-80) | 68.2 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Lee, 2012 | Korea | RCT | 18 | 133 | GEM+PLA | 61(55-68) | 59 | 135 | GEM+PLA+TAR | 59(54-66) | 67 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Leone, 2016 | Italy | RCT | 42 | 44 | GEM+PLA | 64(37-79) | 34 | 45 | GEM+PLA+TAR | 64(47-79) | 37.7 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Li, 2016 | China | RCT | 24 | 25 | GEM | - | - | 25 | GEM+FU | - | - | (1)(2)(3)(4)(5)(6)(7)(8) |
| 25 | FU | - | - | 25 | GEM+FU | - | - | (1)(2)(3)(4)(5)(6)(7)(8) | ||||
| Malka, 2014 | France | RCT | 34 | 74 | GEM+PLA | 62(39-75) | 57 | 76 | GEM+PLA+TAR | 61(35-75) | 57 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Moehler, 2014 | Germany | RCT | 31 | 49 | GEM+TAR | 64(44-83) | 59 | 48 | GEM | 65(36-84) | 52 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Morizane, 2013 | Japan | RCT | 24 | 51 | GEM+FU | 66(39-78) | 52.9 | 50 | FU | 63(49-79) | 56 | (1)(2)(3)(5)(6)(7)(8) |
| Phelip, 2014 | France | RCT | 30 | 18 | FU+PLA | 70(53-80) | 39 | 16 | GEM+PLA | 75(54-81) | 50 | (1)(2)(7) |
| Rogers, 2014 | USA | Retro | 60 | 11 | GEM+PLA | - | - | 16 | GEM+FU | - | - | (1)(2) |
| Santoro, 2015 | Italy | RCT | 33 | 57 | GEM+TAR | (55-74) | 53.4 | 52 | GEM | (55-73) | 44.6 | (1)(2)(3)(4)(5)(6)(7) |
| Sasaki, 2013 | Japan | RCT | 24 | 30 | GEM+FU | 68(47-83) | 53 | 32 | GEM | 75(55-86) | 63 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Sharma, 2010 | India | RCT | 27 | 28 | FU | 47 | 18 | 27 | BSC | 51 | 22 | (1)(2)(3)(4)(5) |
| 26 | GEM+PLA | 49 | 19 | 27 | BSC | 51 | 22 | (1)(2)(3)(4)(5) | ||||
| Valle, 2015 | UK | RCT | 36 | 62 | GEM+PLA+ | 68(60-73) | 55 | 62 | GEM+PLA | 65(60-73) | 45 | (1)(2)(3)(4)(5)(6)(7)(8) |
| Woo, 2014 | Korea | Retro | 45 | 127 | GEM+PLA | 62(35-76) | 56.7 | 217 | FU+PLA | 58(27-82) | 62.8 | (1)(2)(3)(4)(5)(6) |
| Yonemoto, 2007 | Japan | Retro | 52 | 30 | FU | - | 43 | 125 | BSC | - | 61 | (1)(2)(3)(4) |
| 20 | FU | - | 65 | 125 | BSC | - | 61 | (1)(2)(3)(4) | ||||
| 58 | GEM | - | 52 | 125 | BSC | - | 61 | (1)(2)(3)(4) | ||||
Abbreviation: RCT, randomized controlled trial; Retro, retrospective trial; GEM, gemcitabine; PLA, Platinum; FU, fluorouracil; TAR, target agents; BSC, best supportive care; Outcomes: (1) overall survival; (2) progression-free survival; (3) overall response rate; (4) disease control rate; (5) vomiting; (6) nausea; (7) neutropenia; (8) thrombocytopenia